This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.

Written by Dr. Parmis Mojarab, DO·Reviewed by Kim Callender, NP, FNP-BC·Published July 12, 2026·Last reviewed July 12, 2026·Methodology v1.0

GLP-1 medications and telehealth

GLP-1 receptor agonists are the most effective pharmacological weight-management and glycemic-control tools available in 2026. This hub covers the molecules, the brands, compounded options and how to evaluate providers.

Quick answer

GLP-1 (glucagon-like peptide-1) receptor agonists reduce appetite and improve blood-sugar control. The class includes semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), plus older and investigational agents. This hub routes you to molecule guides, brand pages, cost analysis and provider reviews.

Explore this topic

Tirzepatide

Dual GIP/GLP-1 agonist — the highest average trial weight loss

Semaglutide

The most widely used GLP-1 agonist

Best GLP-1 programs

Independently scored provider ranking

GLP-1 cost guide

Every pricing pathway compared

Compounded GLP-1

What compounding is and its current limits

Microdosing

Low-dose protocols: evidence vs marketing

GLP-1 side effects

Common and serious effects across the class

GLP-1 eligibility

Who qualifies and how clinicians decide

Provider directory

Every provider we track

Regulatory contextCompounded drugs are <b>not FDA-approved</b>: the agency does not review them for safety, effectiveness or quality before they are marketed. Federal law also bars compounding drugs that are <b>essentially a copy</b> of a commercially available approved product — a bar that is lifted only while the drug is on the FDA shortage list. Both shortages are over. The FDA declared the tirzepatide shortage resolved on October 2, 2024 and the semaglutide shortage resolved on February 21, 2025, and enforcement discretion ended for all compounders between February 18 and May 22, 2025. On April 30, 2026 the FDA went further, proposing to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list on a finding of no clinical need. Routine compounding of these molecules is therefore no longer lawful on the basis that made the market — a fact most comparison sites still describe as "permanent legitimacy." It is not.

Sources

U.S. Food and Drug Administration — approval and compounding status.
Primary clinical literature cited on child pages.
Our methodology and source standards.

Spotted an error? Submit a correction.